Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer
This study demonstrates the application of multiplex drug combination screening to identify effective synergistic therapies. Co-targeting PI3-kinase and HMG-CoA reductase could be repurposed as a potent combination to treat chemoresistant HGSOC.
Authors
- Paul B. Mullan (ORCID: https://orcid.org/0000-0003-1479-7084)
- Ahlam Ali
- Fiona Furlong (ORCID: https://orcid.org/0000-0002-9206-2297)
- Niamh E. Buckley (ORCID: https://orcid.org/0000-0001-9326-8513)
- Yuling Sun (ORCID: https://orcid.org/0000-0001-5289-4673)
- Syed Umbreen
- Yangyang Wang (ORCID: https://orcid.org/0000-0001-8764-1385)
- Benjamin Pepperrell
Institutions
- University of Wolverhampton (GB)
- Queen's University Belfast (GB)
- PLA Electronic Engineering Institute (CN)
- Cancer Trials Ireland (IE)
- Hefei Urban Planning & Design Institute (CN)
- The Northern Ireland Cancer Centre (GB)
- Anhui Institute of Architectural Research and Design (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1186/s13048-025-01828-7
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Queen's University Belfast
- Higher Education Authority
- Public Health Agency
- Queen's University
- China Scholarship Council